EARLY DETECTION AND PREVENTION METHODS OF ADVERSE DRUG REACTIONS IN MEDICAL PRACTICE

O`ktamova N.B

Tashkent City Alfraganus University Faculty of Medicine, General Medicine Program 3rd-year Student

Boymuratov F.T

Tashkent City Alfraganus University Faculty of Medicine, Department of Pharmacy and Chemistry Associate Professor

Keywords: Keywords: Adverse drug reactions; pharmacovigilance; drug safety; early detection; prevention; risk assessment; clinical monitoring; patient safety.

---

Abstract

Abstract: Adverse drug reactions (ADRs) remain a significant global healthcare concern, contributing to increased morbidity, mortality, and healthcare costs. Early detection and prevention of ADRs are essential to ensure patient safety and improve therapeutic outcomes. Identifying risk factors such as polypharmacy, comorbidities, age-related changes in pharmacokinetics, and genetic predispositions allows clinicians to tailor pharmacotherapy to individual patients. The implementation of pharmacovigilance systems, routine monitoring, patient education, and electronic drug-interaction databases significantly reduces the occurrence of preventable adverse reactions. This article reviews modern strategies for early recognition, monitoring, and prevention of ADRs in clinical practice and emphasizes the role of multidisciplinary collaboration in achieving safe and effective medication use.

---

References

1. World Health Organization (WHO). Pharmacovigilance: Ensuring the Safe Use of Medicines. Geneva: WHO, 2022.

2. Edwards IR, Aronson JK. “Adverse drug reactions: definitions, diagnosis, and management.” Lancet, 2000; 356(9237): 1255–1259.

3. Lazarou J, Pomeranz BH, Corey PN. “Incidence of adverse drug reactions in hospitalized patients.” JAMA, 1998; 279(15): 1200–1205.

4. Pirmohamed M. “Adverse drug reactions.” BMJ, 2006; 332: 501–504.

5. Alomar MJ. “Factors affecting the development of adverse drug reactions.” Saudi Pharmaceutical Journal, 2014; 22(2): 83–94.

6. Uppsala Monitoring Centre. VigiBase: The WHO Global Database of Individual Case Safety Reports. 2023.

7. Bavdekar SB. “Pharmacovigilance in clinical practice.” Indian Journal of Pharmacology, 2015; 47(4): 373–380.

8. Wiffen P, Gill M, Edwards J, Moore A. “Adverse drug reactions in hospital patients.” British Journal of Clinical Pharmacology, 2002; 52(1): 77–83.

9. Rawlins MD, Thompson JW. “Mechanisms of adverse drug reactions.” In: Davies DM, Textbook of Adverse Drug Reactions, 5th ed. Oxford: Oxford University Press, 2003.

10. Bates DW, Cullen DJ, Laird N et al. “Incidence of adverse drug events and potential adverse drug events.” JAMA, 1995; 274(1): 29–34.

11. Eichelbaum M, Ingelman-Sundberg M, Evans WE. “Pharmacogenomics and individualized drug therapy.” Annual Review of Medicine, 2006; 57: 119–137.

12. Leape LL, Bates DW, Cullen DJ et al. “Systems analysis of adverse drug events.” JAMA, 1995; 274(1): 35–43.

13. Baldo BA, Pham NH. “Adverse drug reactions and the immune system: Mechanisms and diagnosis.” Frontiers in Pharmacology, 2013; 4: 91.

14. Shamliyan TA, Kane RL. “Adverse drug events in ambulatory care: Evidence synthesis.” Agency for Healthcare Research and Quality, 2010.